Prevalence of Ischemic Heart Disease and Management of Coronary Risk in Daily Clinical Practice: Results from a Mediterranean Cohort of HIV-Infected Patients
Table 3
Current antiretroviral therapy during coronary event and at the last follow-up visit.
Coronary event (%)
Last follow-up visita (%)
valueb
Without treatment ()
17 (20)
11 (14)
0.3
PI-based regimen ()
33 (41)
35 (43)
0.87
PI (with an unfavorable lipid profile)
22 (67)
13 (37)
0.028
Indinavir/r
7 (21)
2 (6)
0.13
Lopinavir/r
15 (45)
10 (29)
0.23
Fosamprenavir/r
0
1 (3)
1
PI (with a favorable lipid profile)
11 (33)
22 (63)
0.028
Saquinavir/r
2 (6)
0
0.45
Atazanavir/r
6 (18)
11 (31)
0.33
Darunavir/r
3 (9)
11 (31)
0.048
NNRTI-based regimen ()
26 (32)
31 (38)
0.51
Nevirapine
15 (58)
14 (45)
0.5
Efavirenz
11 (42)
17 (55)
0.5
Other treatments ()
6 (7)
4 (5)
0.74
Without treatment
0
5 (33)
1
Nucleoside reverse transcriptase inhibitor
Abacavir
15 (52)
14 (48)
1
aMedian time (IQR) from the coronary event until the last follow-up visit (June 2011): 7 (4; 11) years.
b values express intragroup differences between coronary event time and last visit (after event). PI: protease inhibitors; NNRTI: nonnucleoside analog reverse-transcriptase inhibitors.
